On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...